Bio2Skin, the first clinically skin-preserving biomaterial replacing silicones/acrylate as medical skin adhesivesbroad
Bio2Skin · Horizon Europe grant · 2024-11-01–2026-10-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2024-ACCELERATOR-02 · scheme HORIZON-EIC-ACC · topic HORIZON-EIC-2024-ACCELERATOROPEN-01. CORDIS record →
Objective
External medical devices, such as ostomy pouches, wound dressings or wearable electronic devices, require the use of medical adhesives for their attachment to the skin. However, prolonged use of current medical adhesives is associated with serious adverse skin reactions, MARSI (Medical Adhesives-Related Skin Injuries). This underreported issue is prevalent in 25% of wound care cases and is associated with enormous health care and economic burdens. BH4U aims to address this challenge with Bio2Skin. A patented revolutionary glueless medical adhesive that uses the natural features of the skin to establish a water-based link and overcomes the disadvantages of acrylic/silicone adhesives. Bio2Skin is a bio-based, cost-effective, recyclable solution offering gentle, safe adhesion and kind removal. The product, with a potential of >250M EUR by 2030, will be sold under license to medical adhesive manufacturers and external medical devices manufacturers.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| BESTHEALTH4U LDA | PT | coordinator | €2,492,571 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.